Alkane Resources Ltd (ASX:ALK, OTC:ALKEF) has ended FY2026 in the top half of production guidance after delivering 42,491 gold-equivalent ounces in the June quarter and lifting closing cash by $104 million to $432 million.
The company produced 168,337 gold-equivalent ounces for the full year, placing it in the upper half of its 160,000 to 175,000-ounce guidance range.
The S&P/ASX Small Ordinaries index was weaker on Wednesday, falling 43.70 points, or 1.27%, to 3,390.80.
The move extended recent weakness for the small-cap benchmark, which is now down 56.10 points, or 1.63%, over the past five trading days.
Nexus Minerals Ltd (ASX:NXM) is set to take full control of the Pinnacles Gold Project in Western Australia’s Eastern Goldfields after agreeing to acquire Northern Star Resources Ltd (ASX:NST)’s remaining 10% interest in the project.
The deal lifts Nexus’ ownership of Pinnacles to 100% and will terminate the existing joint venture with Northern Star, giving Nexus full operational and strategic control of the high-grade gold asset.
Lynas Rare Earths Ltd (ASX:LYC, OTC:LYSCF) has deepened its push into the global rare earth magnet supply chain, signing a long-term partnership with South Korea’s JS Link to support the development of a new magnet manufacturing plant in Kuantan, Malaysia.
The deal builds on a memorandum of understanding signed in July 2025 and could provide a significant downstream growth avenue for Lynas, given the exclusive nature of the supply arrangement and the long contract period through to 2038.
Netwealth Group Ltd has secured a major platform agreement with Morgan Stanley (NYSE:MS) Wealth Management Australia, marking its first significant client win from a strategic push into the stockbroking and private wealth market.
Under the deal, Netwealth will provide MSWM advisers with access to a domestic investment platform covering ASX-listed securities, managed accounts, managed funds, cash and term deposits, as well as integrated reporting and a branded mobile experience.
WiseTech Global founder Richard White has stepped down as chairman of the logistics software company, with independent director Raelene Murphy taking over the role as the group moves to address governance concerns and media scrutiny around its billionaire founder.
The company told the ASX that Murphy, who joined the board in January and became lead independent director in May, had been appointed independent chair with immediate effect.
Northern Minerals Ltd (ASX:NTU) has notified Treasury that China-linked investors ordered to sell down their holdings in the company appear to have largely retained their stakes, escalating a foreign investment compliance issue around one of Australia’s key heavy rare earths projects.
The company, which is developing the Browns Range Heavy Rare Earths Project in Western Australia’s Kimberley region, told ASX investors it had reviewed its share register following a divestment order issued by Treasurer Jim Chalmers on May 17.
VanEck is set to launch Australia’s first AI-driven international equity ETF, giving ASX investors access to a portfolio that uses generative reinforcement learning to identify global stock opportunities.
The VanEck Dynamic International Equity ETF (ASX: GOAT) will begin trading on Monday, July 20, and will track the Akros Enhanced World ex Australia Index.
FOS Capital Ltd (ASX:FOS) has strengthened its healthcare infrastructure credentials after securing a lighting contract worth about $1 million for the Monash Medical Clinic Tower Expansion in Victoria.
The contract, awarded to FOS through its wholly owned subsidiary FOS Lighting Pty Ltd, involves the supply of specialised high-performance lighting solutions across the expanded healthcare facility.
Alterity Therapeutics Ltd (ASX:ATH) has received official US Food and Drug Administration meeting minutes confirming a registrational pathway for ATH434, its lead drug candidate for Multiple System Atrophy (MSA).
The FDA minutes confirm the previously announced End-of-Phase 2 meeting outcomes and provide further detail on the planned Phase 3 protocol. Importantly, the regulator agreed that a single pivotal Phase 3 trial, supported by confirmatory evidence, could support approval of ATH434 for the treatment of MSA.
Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) is raising about A$11.12 million before costs through a two-tranche placement, strengthening its balance sheet as it advances its lead cell therapy asset azer-cel through key clinical and regulatory milestones.
The placement follows positive early clinical data from Cohort 3 of Imugene’s ongoing Phase 1b azer-cel study, where the first two evaluable patients in the concurrent BTKi combination cohort achieved complete responses.
SpaceX Corp (NASDAQ:SPCX)’s Starlink mobile ambitions are beginning to sharpen the debate around Australia’s next phase of telecommunications competition, as satellite-to-phone services move beyond emergency messaging and toward broader mobile connectivity.
While current direct-to-phone satellite services remain limited, Starlink’s global network, expanding Direct to Cell technology and existing local partnerships suggest the company could eventually play a more direct role in Australia’s mobile market.